Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides oral solid formulations for ARVs, anti-diabetic, cardiovascular, and PPIs. In addition, the company offers contract development and manufacturing organizational services; and biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. Further, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for LAURUSLABS
Revenue projections for LAURUSLABS

LAURUSLABS's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.

Financial Ratios:

currentRatio 0.000000
forwardPE 54.629692
debtToEquity 44.831000
earningsGrowth 1.719000
revenueGrowth 0.257000
grossMargins 0.570230
operatingMargins 0.202210
trailingEps 15.590000
forwardEps 18.652860

Laurus Labs Limited's forward PE is elevated, which may cap future price gains and even lead to a price correction. This overvaluation risk highlights the importance of considering this metric carefully in combination with other fundamental indicators to evaluate the stock properly.
Positive earnings and revenue growth for LAURUSLABS point to expected business expansion. The company is projected to continue growing its operations, as increasing profits and sales highlight a strong trajectory for further growth in the future.
LAURUSLABS's positive gross and operating margins indicate healthy profitability. These margins reflect the company's ability to generate income efficiently from its operations, signaling strong financial performance and effective cost management.
Laurus Labs Limited's forward EPS exceeding its trailing EPS means the company is expected to be more profitable this year than last. This suggests an upward trend in earnings, with forecasts indicating that Laurus Labs Limited's financial performance will improve in the current financial year.

Price projections:

Price projections for LAURUSLABS
Price projections for LAURUSLABS

LAURUSLABS's price projections have been consistently revised upward, suggesting that analysts are becoming increasingly optimistic about the company's future. This trend reflects confidence in LAURUSLABS's ability to achieve strong financial results.

Recommendation changes over time:

Recommendations trend for LAURUSLABS
Recommendations trend for LAURUSLABS


Analysts' sell bias for LAURUSLABS suggests caution, but investors should base their decisions on a wide range of market indicators. This ensures a more comprehensive view of LAURUSLABS's market potential and provides a better framework for making balanced investment decisions.